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Abstract
Background: Cervical cancer screening is not yet standard of care of women attending HIV care clinics in Africa
and presents operational challenges that need to be addressed.
Methods: A cervical cancer screening program based on visual inspection methods was conducted in clinics
providing antiretroviral treatment (ART) in Abidjan, Côte d’Ivoire. An itinerant team of midwives was in charge of
proposing cervical cancer screening to all HIV-positive women enrolled in ART clinics as well as to HIV-negative
women who were attending the Abidjan national blood donor clinic. Positively screened women were
systematically referred to a colposcopic examination. A phone-based tracking procedure was implemented to
reach positively screened women who did not attend the medical consultation. The association between HIV
status and cervical cancer screening outcomes was estimated using a multivariate logistic model.
Results: The frequency of positive visual inspection was 9.0% (95% CI 8.0-10.0) in the 2,998 HIV-positive women
and 3.9% (95% CI 2.7-5.1) in the 1,047 HIV-negative ones (p <1 0
-4). In multivariate analysis, HIV infection was
associated with a higher risk of positive visual inspection [OR = 2.28 (95% CI 1.61-3.23)] as well as more extensive
lesions involving the endocervical canal [OR = 2.42 (95% CI 1.15-5.08)]. The use of a phone-based tracking
procedure enabled a significant reduction of women not attending medical consultation after initial positive
screening from 36.5% to 19.8% (p <1 0
-4).
Conclusion: The higher frequency of positive visual inspection among HIV-positive women supports the need to
extend cervical cancer screening program to all HIV clinics in West Africa. Women loss to follow-up after being
positively screened is a major concern in cervical screening programs but yet, partly amenable to a phone tracking
procedure.
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Background
Acording to 2008 estimates, invasive cervical cancer
(ICC) is the third most common cancer in women
worldwide with an estimated 530,232 new cases annually
and is responsible for 275,180 deaths. More than 85% of
these new ICCs and 88% of these cancer deaths occur
in resource-limited settings [1]. In sub-Saharan Africa, a
significant association between HIV infection and ICC
has been reported, although it has been much less
strong compared to reports from resource-replete set-
tings [2]. Since 2002, access to antiretroviral treatment
(ART) has been dramatically scaled up with four million
HIV-infected patients accessing ART in sub-Saharan
Africa at the end of 2009 [3]. As the coverage of ART
in low-resource settings continues to improve the prog-
nosis of HIV-infected individuals, it is likely to be trans-
lated into years of life saved [4]. Thus, a focus on long-
term case management is now needed, especially for
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HIV-infected patients receiving ART in sub-Saharan
Africa. In high-resource countries, cytology-based cervi-
cal screening has curbed the incidence of cervical cancer
for decades [5]. Due to human resource and infrastruc-
ture shortages, previous experiences in Côte d’Ivoire as
well as other sub-Saharan countries highlighted a lack of
reliability of cytology-based cervical screening at the
population level [6,7]. Cervical screening procedures
based on the identification of high-risk human papil-
l o m av i r u s e s( H P V )h a v eah i g hc a p a c i t yt od e t e c tp r e -
cancerous cervical lesions [8,9]. However, these
techniques are currently too work-intensive and expen-
sive to be largely implemented. Low cost, cervical
screening procedures based on visual inspection (VI) of
the cervix have been proposed and adapted to resource-
limited settings for years [10-12]. Although having a
lower sensitivity and specificity than HPV tests, they
have shown an equal validity compared to cytology in
HIV-negative as well as HIV-positive women in
resource-limited settings [13,14]. A successful experi-
ence with the implementation of such a cervical screen-
ing procedure targeting HIV-infected women has been
recently reported in Zambia but experiences from other
parts of sub-Saharan Africa are limited [15,16]. We
therefore sought to compare some of the critical opera-
tional and clinical outcomes of a cervical cancer screen-
ing based on VI methods among HIV-negative and
HIV-positive women in Abidjan, Côte d’Ivoire.
Materials and methods
Study population
Our study was a one-shot cervical cancer screening pro-
cedure based on visual inspection methods implemented
in a sample of HIV care clinics providing ART in Abid-
jan and involved in “the International epidemiological
Database to Evaluate AIDS (IeDEA) in West Africa”
http://mereva.net/iedea[17]. Due to logistic and financial
constraints, only three of the six adult HIV clinics
involved in the IeDEA collaboration were invited to par-
ticipate. Two nongovernmental organizations, the
ACONDA-CePReF (Yopougon) and the ACONDA-
MTCT plus (Abobo) together with the national center
for blood transfusion (CNTS) (Treichville) were selected
in order to cover all the three districts where the IeDEA
West Africa sites are already implemented in Abidjan.
The CNTS was also selected for its capacity to recruit
HIV-negative women. From August 2009 to November
2010, a mobile team composed of three certified mid-
wives and a senior gynaecologist was in charge of pro-
posing cervical cancer screening to all HIV-positive
women attending these three clinics for their routine
HIV follow-up. The clinics were sequentially involved
for a period of six (CePReF, Yopougon), four (MTCT
plus, Abobo) and seven (CNTS, Treichville) months,
according to the number of women usually attending
these services. From May to November 2010, a referent
group of HIV-negative women who attended the CNTS
clinic for blood donation were also proposed this same
cervical cancer screening procedure. Identical exclusion
criteria (i.e. history of cervical cancer or total hysterect-
omy, aged < 25 or > 65 years, pregnancy > 20 weeks)
were applied to both HIV-negative and HIV-positive
women. Midwives and doctors were not blinded to HIV
status.
Screening procedure
After obtaining written informed consent from the women
and collecting participant’s history, midwives conducted a
gynaecological examination. An unlubricated bivalve spec-
ulum was inserted into the vagina by the midwife who
examined the cervix using a halogen focus lamp and iden-
tified the squamocolumnar junction (SCJ). After cleaning
away any excess mucus using a cotton swab, a five percent
acetic acid solution was applied to the cervix for visual
inspection with acetic acid (VIA). Findings were visible
one minute after application. A positive VIA was charac-
terised by a well-defined, dense acetowhite area with regu-
lar or irregular margins, close to or abutting the SCJ in the
transformation zone or when the whole cervix or a cervi-
cal growth turned acetowhite. Following VIA, visual
inspection with Lugol’s iodine (VILI) was also performed.
A positive VILI test was characterised by a dense, thick,
bright, mustard-yellow or saffron-yellow iodine non-
uptake area seen in the transformation zone, close to or
abutting the SCJ or when the entire cervix or a cervical
growth turns densely yellow. Results of VIA and VILI
were both classified as negative, positive or indicative only
of ICC according to the International Agency for Research
on Cancer (IARC) training manual and recorded on the
study questionnaire following each test [18]. The use of
both VIA and VILI for cervical cancer screening relies on
previous reports that showed an improvement in diagnos-
tic performance by combining the two methods [19]. Mid-
wives mapped positive lesions with both VIA and VILI on
the clinical form and assessed the following items: number
of positive lesions, number of quadrants of the cervix
involved and if the lesion(s) extend to the endocervical
canal. Positively screened women as well as women with
inconclusive examination were systematically referred for
a colposcopic examination. Women with a negative exam-
ination but presenting with cervical inflammatory lesions
were systematically referred for repeat VIA and VILI tests
three weeks after being prescribed appropriate antibiotics.
Prior to the study conduct, midwives were trained to per-
form and report VIA and VILI during a four-day intensive
course. Additional training included discussion and review
of pictures of normal and abnormal cervix as well as
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given during the study period. The colposcopic consulta-
tion was carried out in the same clinics where the women
were initially screened, on a weekly basis, by a senior
gynaecologist. Referred women were assessed with colpo-
scopy and directed biopsies were performed if needed and
sent to the Abidjan university hospital pathology unit of
Abidjan. Histopathological findings were categorized into
five classes: normal or non-neoplasic changes, cervical
intraepithelial neoplasia grade 1 (CIN1) including HPV
changes, CIN2, CIN3 and ICC as described elsewhere
[13]. Women with positive or inconclusive VI were sys-
tematically addressed on the same week or a week after to
a medical consultation. If not showing up to this first visit,
women were contacted by phone calls to schedule another
visit. After a maximum of three attempts (one per week),
women who did not show-up or who could not be con-
tacted were considered as loss to follow-up (LTFU) and
called back once to state their reason for not attending. To
enhance participation to the cervical cancer screening in
our targeted population and obviate LTFU, women were
orally counselled about the risk of cervical cancer and the
potential benefits of an early detection. Group counselling
was provided by midwives on a daily basis in the waiting
rooms of the HIV clinics or the CNTS. Leaflets to sensitize
women to cervical cancer and its prevention were also dis-
tributed during these sessions. Patients with CIN or cancer
were offered appropriate follow-up and treatment accord-
ing to local recommendations. The entire screening proce-
dure was free of charge as well as the ensuing treatment in
case of positive findings. This study was approved by the
national ethics committee for HIV research in Côte
d’Ivoire.
Statistical analysis
Analyses were first conducted to compare the women
characteristics according to HIV status using Pearson’s
c2o rF i s h e r ’s exact test, when appropriate, for qualita-
tive variables, and t-test or Wilcoxon test for quantita-
tive variables. A logistic regression model was used for
univariate and multivariate analyses of the association
between the main outcome of the cervical screening test
(i.e. positive visual inspection, inflammatory lesions of
the cervix, unsatisfactory examination) and the HIV sta-
tus. Proportions and odds ratio (OR) estimates were
reported with their 95% confidence intervals (95% CIs).
All statistical analyses were performed using SAS soft-
ware, version 9.1 (SAS Institute Inc, Cary, NC, USA).
Results
General characteristics
Of the 4,208 women who attended the cervical cancer
screening consultations from August 2009 to November
2010, 162 (3.9%) were not eligible for visual inspection
tests and excluded. Three per cent of the HIV-positive
women were excluded, a significantly lower proportion
than the 6.3% figure among the HIV-negative women (p <
10
-4). Among excluded women, 89% of the HIV-negative
women were < 25 years compared to 65% in HIV-positive
women (p <1 0
-3). Six HIV-positive women and two HIV-
negative women did not give their consent to participate
in the present study. A total of 2,998 HIV-infected women
and 1,048 HIV-negative women were effectively enrolled.
The baseline characteristics of these women according to
their HIV status are summarized in table 1.
The 2,998 HIV-positive women had a median CD4
count of 291 [inter-quartile range (IQR) 156-461] cells/
mm
3 at enrolment in HIV care and 452 [IQR 301-621]
cells/mm
3 at last known follow-up visit for HIV infec-
tion. The median time between cervical screening and
last known CD4 count measure was 4 [IQR 2-6]
months. Current ART use was reported in 2,267 (75.6%)
HIV-positive women with a median time since ART
initiation of 28 months [IQR 12-50].
Cervical screening outcomes
The frequency of positive visual inspection in HIV-posi-
tive women was 9.0% (95% CI 8.0-10.0), significantly
h i g h e rt h a nt h e3 . 9 %e s t i m a t e( 9 5 %C I2 . 7 - 5 . 1 )f o u n di n
HIV-negative women (p <1 0
-4). Main results of the cer-
vical screening program according to HIV status are
summarized in Figure 1.
Of the 414 women referred to colposcopic examination
for positive or inconclusive results with VIA and/or VILI,
151 (36.5%) did not attend the initial gynaecologist consul-
tation scheduled during the screening visit. After the appli-
cation of a systematic phone call tracking procedure to
these 151 women, 69 finally attended the colposcopic con-
sultation after being scheduled another appointment. A
total of 82 (19.8%) women (73 HIV-positive and 9 HIV-
negative) were LTFU. The LTFU rate of women referred
for positive or inconclusive visual inspection did not sig-
nificantly differ in HIV-positive women (20.9%) compared
to HIV-negative women (13.8%) (p = 0.18). Of the 332
women who effectively attended the gynaecologist consul-
tation and underwent a colposcopic examination, 137
(41.3%) were finally considered as negative. Directed biop-
sies of the cervix were performed in the remaining 195
women with suspected premalignant or malignant lesions
of the cervix. Results were as follow: 132 grade 1 CIN, 14
grade 2 or 3 CIN, six ICC and 43 non-malignant findings.
Women with ICC were all refereed to a tertiary hospital
and underwent radical hysterectomy except one who died
before the intervention. The frequency of precancerous
cervical lesions or ICC was 4.4% (95% CI 3.7-5.1) in HIV-
positive women and 1.9% (95% CI 1.1-2.7) in HIV-negative
women (p <1 0
-3). The association between HIV status
and the main outcomes of the cervical screening tests is
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than twice as likely to be VI-positive than the negative
ones in multivariate analysis (OR = 2.28, 95% CI 1.61-
3.23) after adjustment on age, parity and number of life-
time sexual partners. Among the 309 women with positive
VI, multiple lesions were found in 27.6% of HIV-positive
women and 15.6% of HIV-negative women (p =0 . 0 8 ) .
Lesions with several quadrants of the cervix involved were
reported in 34.1% of HIV-positive women compared to
68.6% in HIV-negative women (p <1 0
-4). In HIV-positive
women, 50% of the positive lesions at visual inspection
extended to the endocervical canal compared to 26.8% in
HIV-negative women (p <1 0
-2). In multivariate analysis,
an association was found between the HIV-positive status
and the identification of lesions involving several quad-
rants of the cervix (adjusted OR = 4.49, 95% CI 2.17-9.28)
and the extensions of the lesions to the endocervical canal
(adjusted OR = 2.42, 95% CI 1.15-5.08) (Table 2).
Loss to follow- up
Among the 82 women LTFU, 64 were reached by tele-
phone and 55 reported the reason for not attending the
physician consultation: 39 (70.9%) did not attend for
financial reasons (expected cost related to transport,
diagnosis and treatment in case of confirmed cervical
lesions), 14 (25.5%) for lack of time (being busy or sim-
ply forgot) and two women (3.6%) reported not willing
to know more about their cervical cancer status.
Discussion
Outcomes of cervical screening according to HIV status
A higher rate of precancerous lesions of the cervix or
ICC was found in HIV-positive women, consistent with
previous reports from sub-Saharan Africa [2]. This find-
ing confirms the need to urgently implement routine
cervical cancer screening programs in HIV clinics in
West Africa. Regardless of HIV status, the frequency of
positive VI and histologically confirmed CIN lesions was
relatively low compared to other reports in Africa. In
the southern Africa region, a higher frequency of posi-
tive VI had been previously reported in HIV-infected
women, ranging from 32.6% to 43.7% in South Africa
and Zambia, respectively [8,20]. Recent cervical screen-
ing program based on VIA conducted in Mali and Tan-
zania among 14,141 and 10,378 women regardless of
HIV status, reported 1,005 (7.1%) and 274 (2.6%) of
Table 1 Characteristics of the screened population according to HIV status (n = 4,046) in Abidjan, Côte d’Ivoire.
HIV+ HIV- p Total
N = 2,998 N = 1,048 N = 4,046
Age (years), median [IQR]* 36 [32 42] 34 [29 42] < 10
-4 36 [31 42]
Formal education, n (%) <1 0
-4
No 757 (25.3) 134 (12.8) 892 (22.0)
Yes 2,241 (74.7) 914 (87.2) 3,154 (78.0)
Monthly income (USD), n (%) < 10
-4
] 40 628 (21.0) 176 (16.8) 804 (19.9)
[40 80[ 1,296 (43.2) 305 (29.1) 1,601 (9.6)
[80 794 (26.5) 547 (52.2) 1,341 (33.1)
Unknown 280 (9.3) 20 (1.9) 300 (7.4)
Tobacco use†, n (%) 0.15
No 2,954 (98.5) 1,039 (99.1) 3,993 (98.7)
Yes 44 (1.5) 9 (0.9) 53 (1.3)
Marital status, n (%) 0.29
Married or cohabitant 1,345 (44.9) 490 (46.8) 1,835 (45.4)
Single, divorced or widowed 1,653 (55.1) 558 (53.2) 2,211 (54.6)
Number of lifetime sexual partners, n (%) < 10
-4
< 5 1,312 (44.0) 608 (58.4) 1,920 (47.7)
≥ 5 1,669 (56.0) 433 (41.6) 2,102 (52.3)
Age at first sexual intercourse or at < 10
-4
marriage (years), median [IQR] 17 [15 18] 18 [16 19] 17 [15 18]
Parity, n (%) <1 0
-4
0 458 (15.3) 336 (32.1) 794 (19.6)
≥ 1 2,539 (84.7) 712 (67.9) 3,251 (80.4)
The IeDEA West Africa collaboration, 2009-2010.
* Inter Quartile Range
† Formal or current consumers of smoked and/or chewed tobacco
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HIV-positive women attending 
cervical screening consultation 
n=3090 
Eligible women 
n=2998 (97.0%) 
Exclusions* n=92 (3.0%) 
Not evaluable 
SCJ not visible 
n=81 (2.7%) 
Positive VI 
n=245 (8.2%)  
Normal VI† 
n=2382 
(79.4%) 
 HIV-positive women referred for colposcopic examination (n=349) 
268 positive VI: 9.0% (95% CI 8.0-10.0) 
230 positive with VIA: 7.7% (95% CI 6.7-8.6) 
255 positive with VILI: 8.5% (95% CI 7.5-9.5) 
132 histological confirmations 
4.4% (95% CI 3.7-5.1) 
CIN 1 (n=115), CIN 2/3 (n=14), ICC (n=3) 
73 LTFUۆ 
20.9% (95% CI 16.7-25.2) 
Inflammatory lesions n=290 (9.7%) 
LTFU, n=105 (36.2%) 
Positive VI, n= 23/185 (12.4%) 
HIV-negative women attending 
cervical screening consultation 
n=1118 
Eligible women 
n=1048 (93.7%) 
Exclusions* n=70 (6.3%) 
Not evaluable 
SCJ not visible 
n=24 (2.3%) 
Positive VI 
n=38 (3.6%)  
Normal VI† 
n=922 
(88.0%) 
 HIV-negative women referred for colposcopic examination (n=65) 
41 positive VI: 3.9% (95% CI 2.7-5.1) 
20 positive with VIA: 1.9% (95% CI 1.1-2.7) 
37 positive with VILI: 3.5% (95% CI 2.4-4.6) 
20 histological confirmations 
1.9% (95% CI 1.1-2.7) 
CIN 1 (n=17), CIN 2/3 (n=0), ICC (n=3) 
9 LTFUۆ 
13.8% (95% CI 5.5-22.2) 
Inflammatory lesions n=64 (6.1%) 
LTFU, n=10 (15.6%) 
Positive VI, n= 3/54 (5.5%) 
Figure 1 Patients flow according to HIV status in the IeDEA West Africa cervical screening project in Abidjan, Côte d’Ivoire, 2009-
2010.*Women excluded for at least one of the following criteria: history of cervical cancer or total hysterectomy, aged < 25 or > 65 years,
pregnancy > 20 weeks or refusal to participate in the present study †Normal VI Counselled for control at 1 year ∫ Inflammatory lesions referred
for other VI tests at 3 weeks ǂ Women addressed to the medical consultation who did not show-up and who could not be contacted after a
maximum of three attempts (one per week) were considered as loss to follow-up. Abbreviations: ICC Invasive Cervical Cancer, CIN cervical
intraepithelial neoplasia, SCJ squamocolumnar junction, VI visual inspection, VIA visual inspection with acetic acid, VILI visual inspection with
Lugol iodine, LTFU loss to follow-up.
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Botswana, a cervical cancer screening programme based
on VIA conducted in 2,175 HIV-positive women
reported 331 (15.2%) histologically confirmed CIN [23].
Discrepancies in the frequency of positive VI and pre-
cancerous lesions according to VI-based studies might
be partly related to the limited reproducibility of these
screening methods as well as inclusion criteria such as
age that differed according to studies. These regional
disparities might also be related to other factors such as
cultural differences in sexual life (polygamy, number of
sexual partners) that have an influence on sexually
transmitted viruses such as oncogenic HPV and finally
on the burden of cervical malignancies in sub-Saharan
Table 2 Association between the main outcomes of the cervical screening tests based on visual inspection methods
and HIV status in Abidjan, Côte d’Ivoire.
Univariate Multivariate*
n/N OR 95% CI p OR 95% CI p
Eligible women who underwent a cervical screening with acetic acid and Lugol iodine (n = 4,046)
Positive VI† <1 0
-4 <1 0
-4
HIV-negative 41/1,048 1 1
HIV-positive 268/2,998 2.41 1.72-3.37 2.28 1.61-3.23
Positive VIA <1 0
-4 <1 0
-4
HIV-negative 20/1,048 1 1
HIV-positive 230/2,998 4.27 2.69-6.78 4.02 2.49-6.48
Positive VILI <1 0
-4 <1 0
-4
HIV-negative 37/1,048 1 1
HIV-positive 255/2,998 2.54 1.79-3.61 2.34 1.63-3.36
Clinical cervicitis < 10
-3 <1 0
-4
HIV-negative 64/1,048 1 1
HIV-positive 290/2,998 1.65 1.24-2.18 1.86 1.38-2.50
No visualisation of the SCJ 0.47 0.45
HIV-negative 24/1,048 1 1
HIV-positive 81/2,998 1.18 0.75-1.88 1.2 0.74-1.94
CIN of any grade‡ 10
-3 <1 0
-2
HIV-negative 20/1,048 1 1
HIV-positive 132/2,998 2.36 1.47-3.81 2.13 1.31-3.45
Positively screened women with acetic acid and/or Lugol iodine (n = 309)
Multiple lesions 0.08 0.10
HIV-negative 6/41 1 1
HIV-positive 74/268 2.25 0.90-5.51 2.13 0.85-5.35
Lesions with several < 10
-4 <1 0
-4
quadrants of the cervix
involved
HIV-negative 14/41 1 1
HIV-positive 184/268 4.22 2.11-8.47 4.49 2.17-9.28
Extension to the endocervical canal < 10
-2 0.02
HIV-negative 11/41 1 1
HIV-positive 134/268 2.64 1.27-5.50 2.42 1.15-5.08
Patients lost to follow-up∫ 0.32 0.26
HIV-negative 5/41 1 1
HIV-positive 50/268 1.65 0.62-4.42 1.89 0.63-5.69
The IeDEA West Africa collaboration, 2009-2010.
* Adjusted for age group in years ([25-35],[35-45],[45-55] and [55-65]), parity (yes vs. no) and number of lifetime sexual partners (< 5 vs. ≥5)
† Positive visual inspection with VIA and/or VILI
‡ Histological precancerous or cancer lesions confirmed in women who underwent colposcopic examination and directed biopsies
∫ Positively screened women referred for a colposcopic consultation who did not attend the appointment after a telephone-based tracking procedure
Abbreviations: OR Odds ratio, CI Confidence interval, VIA Visual inspection with acetic acid, VILI Visual inspection with Lugol iodine, SCJ Squamocolumnar
junction, CIN Cervical intraepithelial neoplasia.
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study conducted in Côte d’Ivoire that found similar fre-
quencies of positive VIA in 2,713 HIV-positive (11%)
and 743 HIV-negative women (3%) [24]. Although it
remains unclear whether the HIV epidemic has
impacted the incidence of ICC in sub-Saharan Africa, it
is noteworthy that high ICC incidences are reported in
countries with the highest prevalence of HIV [25].
Cervical screening programs based on VIA and/or
VILI have previously demonstrated to be an adapted
alternative to cytology in both HIV-positive and HIV-
negative populations from resource-limited settings
[13,14]. To avoid LTFU and tackle human resource
shortage for cervical cancer diagnostic and treatment
algorithms, a ‘see-and-treat’ approach proposing an
immediate cryotherapy for positively screened cervical
lesions with limited extension has been developed and
implemented [11,26,27]. Usual criteria for postponing an
immediate cryotherapy in a ‘see-and-treat’ strategy are
as follows: lesions occupying > 75% of the transforma-
tion zone or more than three quadrants of the cervix,
lesions extending into the endocervical canal that can-
n o tb ec o m p l e t e l yv i s u a l i z e da n dl e s i o n st o ol a r g et of i t
the largest available cryotherapy probe [27]. Our study
was not initially designed to perform a ‘see-and-treat’
strategy. Thus, we did not formally address the rate of
ineligible women referred for a delayed treatment. How-
ever, based on clinical reports of midwives who per-
formed the visual inspection, a high frequency of
extensive lesions was observed in our study population,
especially in HIV-infected women. This might directly
impact on their risk of being in need for a delayed treat-
ment. In Zambia, results from a ‘see-and-treat’ program
using VIA in 8,823 women attending HIV care clinics
reported that 2,378 (26.9%) were immediately treated
with cryotherapy and 1,477 (16.7%) referred for physi-
cian evaluation [20]. In Botswana, a ‘see-and-treat’ pro-
gram based on VIA in 2,175 HIV-positive women
reported that 253 (11.6%) effectively underwent an
immediate cryotherapy and 575 (27.3%) were referred
for a delayed medical evaluation [23]. Reports from
Ghana and India on ‘see-and-treat’ programs in the gen-
eral population found a proportion of ineligible women
to an immediate cryotherapy of 2.5% and 25.2%, respec-
tively [26,27]. Thus, the follow-up of ineligible women
for an immediate treatment remains a major issue, espe-
cially in HIV-positive populations.
Loss to follow-up
The proportion of positively screened women who did
not attend the medical consultation prior to the appli-
cation of a tracking system is consistent with a pre-
vious report from Zambia where 40.8% of positively
screened women ineligible for an immediate
cryotherapy and referred to a physician examination
did not show up [20]. The adjunction of a simple
tracking procedure based on telephone calls inviting to
the mobile medical consultation for colposcopic exami-
nation allowed a major reduction in the proportion of
women LTFU. However, a significant rate of LTFU
remained. A particular effort must be done to sensitise
women to the importance of cervical malignancies and
the advantages of an early identification of precancer-
ous lesions of the cervix. Finally, the implementation
of a ‘see-and-treat’ approach should be incorporated
into cervical screening in our West African network
considering the experience reported in Zambia among
others. However, even if a single visit approach is
used, an important proportion of HIV-positive women
presenting with more extensive lesions will not be eli-
gible for this ‘see-and-treat’ approach. Additional
research is needed in order to more efficiently reduce
the attrition proportion in cervical cancer screening
programs. Studies exploring reasons for being LTFU as
well as alternative interventions to minimize it need to
be developed.
Limitations
Because only women who were VI positive underwent
histological sampling, the performance of VI could not
be assessed. Accuracy studies on VI showed contrasting
results. While a recent meta-analysis mostly based on
observational studies reports a 80% sensitivity (range,
79%-82%) and a 92% specificity (range, 91%-92%) of
VIA in detecting high-grade precancerous lesions [28],
several randomised trials have shown poorer perfor-
mance of VIA (sensitivity of 55%) compared to HPV
testing (sensitivity 90%) in both HIV-negative and HIV-
positive women [9,29]. As cytology or HPV testing are
currently not available, we believe that VI is the most
appropriate approach that can at least promote the
awareness and initiate the infrastructure for building
cervical cancer screening in HIV clinics in Côte d’Ivoire.
However, the true performance of VI in this particular
context remains to be evaluated. The results reported
from this sample of HIV care clinics might not be
directly extrapolated to other clinics in West Africa,
especially those not located within the proximity of a
referral hospital. Nevertheless, the participation of
clinics of various sizes and from different health care
levels enabled us to extend our findings to at least the
HIV care system of Côte d’Ivoire. VI of the cervix
remains highly related to the operator skills and subject
to misclassification bias. Despite an adapted initial train-
ing of midwives associated with refresher courses during
the study period, a high and sustained proportion of
positively screened women were considered negative
after colposcopic examination and did not undergo
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Page 7 of 9directed biopsy. The rate of false positivity according to
colposcopic results was higher compared to prior accu-
racy studies conducted by IARC in Africa and India
were 2,887 (33%) of the 8,848 women with positive VIA
were recused for a directed biopsy [12]. These differ-
ences probably reflect the wide range in accuracy para-
meters (Se, Sp, PPV and NPV) of VI related to the
subjective, provider-dependent nature of the test and
the underlying frequency of disease. However, when
considering a ‘see-and-treat’ approach based on VI, a
significant part of positively screened women might be
over-treated with cryotherapy. Although the short-term
safety of cryotherapy performed immediately after VI
has been relatively well addressed, its long-term safety,
especially in HIV-infected women remains to be
explored [30]. Alternative screening strategies including
more accurate and reproducible tests such as the rapid
HPV test will ultimately be needed to enhance the per-
formance of screening for the identification of precan-
cerous lesions.
Conclusion
We confirm that HIV-infected women are at higher risk
of presenting a positive cervical screening test as well as
histological precancerous lesions compared to HIV-
negative women, highlighting the need to extend cervi-
cal cancer screening to all HIV care clinics in West
Africa. Specific issues related to visual inspection out-
comes according to HIV status were identified such as
more extensive cervical lesions in HIV-positive women,
leading to a potentially lower number of women eligible
for a ‘see-and-treat’ approach. Regardless of HIV status,
LTFU was a main barrier limiting the sustainability of
this cervical cancer screening approach. However, the
u s eo fas i m p l et e l e p h o n er e c a l le n a b l e das i g n i f i c a n t
r e d u c t i o ni nL T F U .R e a s o n sr e p o r t e db yw o m e nw h o
did not attend colposcopic consultation suggested that
interventions to sensitise women to the benefits of an
early detection and treatment of precancerous cervical
lesions are essential to prevent LTFU. Additional studies
exploring the determinants associated with LTFU as
well as alternative interventions that could significantly
impact on LTFU need to be developed.
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